Recent advances in cancer immunotherapy suggest that manipulation of the immune system to enhance the anti-tumor response may be a highly effective treatment modality. One understudied aspect of immune surveillance is anti-angiogenic surveillance, the regulation of tumor angiogenesis by the immune system, independent of tumor cell lysis. CD4 + T cells can negatively regulate angiogenesis by secreting anti-angiogenic factors such as thrombospondin-1 (TSP-1). In tumor-bearing mice, we show that a Th1-directed viral infection that triggers upregulation of TSP-1 in CD4 + and CD8 + T cells can inhibit tumor angiogenesis and suppress tumor growth. Using bone marrow chimeras and adoptive T cell transfers, we demonstrated that TSP-1 expression in the T cell compartment was necessary and sufficient to inhibit tumor growth by suppressing tumor angiogenesis after the viral infection. Our results establish that tumorigenesis can be stanched by anti-angiogenic surveillance triggered by an acute viral infection, suggesting novel immunological approaches to achieve anti-angiogenic therapy.
͵

Introduction
Recent clinical trials manipulating the immune system suggest that the latest iterations of immunotherapy may be highly efficacious for cancer treatment (1) (2) (3) . Following successful manipulation of the immune system to achieve direct tumor cell lysis, other groups have targeted the tumor vasculature.
One approach uses engineered T cells with chimeric antigen receptors (CARs) targeting antigens specifically expressed by tumor endothelial cells. (4, 5) . Additionally, vaccines targeting tumor endothelium have been utilized in mouse models with moderate success (6) (7) (8) . Immunotherapies targeting the tumor vasculature enhance the immune system's ability to block tumor angiogenesis, referred to here as 'anti-angiogenic surveillance'.
Anti-angiogenic surveillance is the negative regulation of the endothelium by the immune system during tumor growth. Lymphocyte subsets produce specific angiogenic regulators. For example, VEGF is highly expressed by T regulatory cells, while the anti-angiogenic protein IFN-γ is secreted by CD8 + , CD4 + , and NK cells (9, 10). Thus, T cell-secreted VEGF and IFN-γ play opposing roles regulating tumor angiogenesis and tumor growth (9, 11, 12) . Anti-angiogenic surveillance has begun to be appreciated as a unique anti-tumor facet of traditional immune surveillance (12) (13) (14) . However, the mechanisms by which the immune system regulates tumor vasculature are not understood. It is unclear whether the overall effect of an activated immune system is pro-or anti-angiogenic during tumor growth, and is likely to be context dependent.
Tumor cells pose a unique challenge for the immune system in that they require the recognition of subtle differences between normal and disease state. Cancer immunotherapy has focused on redirecting and enhancing the anti-tumor immune response through adoptively transferring ex vivo expanded cells or through vaccination strategies against tumor antigens. Different from tumor cell-directed approaches, there is evidence that acute activation of the immune system by a pathogen results in a bystander effect on tumor growth (15, 16) . Studies using mouse models have revealed that acute infection with Toxoplasma Ͷ (LCMVa) have anti-tumor effects, whereas chronic infections such as Hepatitis C promote tumor growth, making the relationship between an active immune response and tumor growth unclear (16, 17) . There have been several attempts to use controlled infection as a means of treating cancer, but have been met with limited success. Studies using acute infections investigated the mechanisms mediating the observed antitumor effect (15) . Surprisingly, mice lacking key components of the cytolytic immune response, including inducible NO synthase (iNOS), perforin, tumor necrosis factor-alpha (TNF-α), and IL-12, still demonstrated a significant anti-tumor effect after acute infections that predominantly induced a Th1 directed immune response (16) . Histological analysis of tumors isolated from infected mice revealed a significant suppression of tumor vascularization, presumably inhibiting expansion of tumor mass. The mechanism by which immune activation towards a non-tumor cell target could inhibit tumor angiogenesis remains unclear.
The endogenous angiogenesis inhibitor Thrombospondin-1 (TSP-1) is expressed by immune cells and could mediate anti-angiogenic surveillance (13) . TSP-1 is a homotrimeric, extracellular matrix protein that is highly expressed in platelets, stromal cells and endothelial cells and is a potent negative regulator of endothelial cell proliferation and migration (18) . TSP-1 expression negatively correlates with vascularity, tumor growth and disease progression in several cancer types (19) (20) (21) . We have previously shown that TSP-1 is expressed by T cells and that splenocyte-derived TSP-1 is critical for tumor regression in an inducible Myc-regulated lymphoma model. Lymphomas relapsed in the absence of splenocyte-derived TSP-1, indicating the importance of TSP-1 in sustained tumor regression (13) .
Here we show that T cell activation in response to a number of antigens including tumor antigen, bacterial toxin, virus and antibody treatment upregulates TSP-1 expression. We use the Armstrong strain of lymphocytic choriomeningitis virus (LCMVa), an acute Th1-inducing virus, to activate the immune system and upregulate TSP-1 expression. LCMVa infection causes a robust proliferation of T cells, particularly CD8 + cells, over an eight-day expansion phase followed by rapid contraction. It is easily ͷ tumor growth. We demonstrate that in wild-type mice, LCMVa infection significantly suppresses tumor growth however this effect is lost is Tsp1 -/-mice. Utilizing Tsp1 -/-and Rag1 -/-mice, we generated bone marrow chimeras and performed adoptive T cell transfers to confirm that TSP-1 in the T cell compartment is necessary and sufficient to suppress tumor growth after LCMVa infection by inhibiting tumor
angiogenesis. Our studies demonstrate direct anti-angiogenic activity of T cells and identify TSP-1 as a link between acute infection, T cell activation, and anti-angiogenic surveillance, indicating that regulation of T cell expression of TSP-1 may be a novel approach to inhibit tumor angiogenesis.
Materials and Methods
Mice
C57Bl/6 mice, Rag1 -/-mice were from The Jackson Laboratory. Balb/c SCID mice were from Massachusetts General Hospital animal breeding facility. Tsp1 -/-mice were obtained from Dr. Jack
Lawler (BIDMC/Harvard Medical School, described in (22)). Mice were males 5-8 weeks old. All animal experiments were performed according to protocols approved by the University of Pennsylvania IACUC.
In vitro stimulation of T cells and splenocytes
Spleens were filtered through 100uM filters in PBS, pelleted, and red blood cells lysed using ACK were lysed in RIPA buffer. For western blotting, membranes were incubated with TSP-1 antibody clones SPM-321 and A6.1 (1:500, Santa Cruz) or β-actin antibody (1:3000, Sigma) followed by HRP labeled secondary antibodies, and detected using ECL solution. Densitometry analysis was performed on minimally exposed blots using ImageJ software (http://rsbweb.nih.gov/ij/) to determine a TSP-1:actin ratio for each time point, and then this ratio for each time point compared to day 0 was calculated.
Tube formation assay
WT and Tsp1
-/-T cells were isolated and cultured as described above for 72 hours ± CD3/CD28 
Microarray
Cell sorting and data analysis for mRNA microarray is described in (23 ͺ CD3 staining, sections were deparrafinized by xylene and EtOH, antigen retrieval was performed with Proteinase K at 50 degrees for 40 min, and sections were blocked with 10% mouse serum in PBS. Slides were then incubated O/N at room temp with anti-TSP-1 clones SPM-321 and A6.1 (1:500, Santa Cruz) and anti-CD3 (1:300, Dako). Secondary antibodies were Alexa 488 goat anti-rat, Alexa 594 goat antirabbit, Alexa 488 goat anti-rabbit, or Alexa 594 rat anti-mouse (1:1500, Invitrogen) and nuclei were identified with Hoechst33342 (1:1000, Invitrogen). Five random 10x magnification pictures were taken of each slide, the area of CD31 + structures, number of visible lumens, number of vessels, and number of vessels > 100 μm was counted, and an average for each tumor was found. Vessel structures for all tumors within a treatment group were averaged to determine average and standard deviation.
Flow cytometry
Flow cytometry was performed on cells from whole spleens or on tumors after digestion in ͻ one hour at 37 degrees C with shaking. Tumor homogenates were then passed through a 100 μm strainer to obtain a single cell suspension, and CD8 or CD45 cells were isolated using anti-CD8 or anti-CD45 beads for positive selection in magnetic columns per manufacturer's protocol (Miltenyi). For western blots, CD8 + cells were then incubated for 4 hours with Brefeldin-A in splenocyte medium before cells were lysed using RIPA. For cytospins, 150,000 CD45 + cells per slide were immediately added to slides.
Slides were then fixed in 4% paraformaldehyde and immunofluorescent staining was performed with TSP-1 and CD3 antibodies as described above.
Results
Thrombospondin-1 expression is increased in activated T cells.
The growth of mouse tumor cells in immunocompromised SCID mice is accelerated in comparison to the growth of the same tumors in syngeneic immunocompetent wild-type (WT) mice (Fig.
S1a
). This difference has been attributed to the lack of immune surveillance in SCID mice due to the absence of T and B cells. Additionally, the spleen, a highly vascularized organ primarily comprised of lymphocytes, is only rarely the site of tumors despite its potential as a site for metastatic seeding. Of note, the highest expression of the endogenous angiogenesis inhibitor, thrombospondin-1 (TSP-1), outside of circulating platelets is in the spleen (Fig. 1a) . While TSP-1 expression is similar between nonlymphoid organs in WT and immunocompromised mice, we found significantly decreased TSP-1 expression in the spleens of lymphocyte-deficient SCID and Rag1 -/-mice as compared to WT mice, implicating lymphocytes as another source of TSP-1 (Fig. 1a) . To understand the role of lymphocyte derived TSP-1, we examined TSP-1 expression after lymphocyte activation and found it to be dramatically upregulated after antibody stimulation of the TCR or by exposure to bacterial lipopolysaccharide (LPS) in vivo (Fig. 1b) ͳͲ mice. TSP-1 expression was markedly upregulated as compared to non-tumor bearing controls (Fig.   1c,d) . To narrow the relevant TSP-1 expressing lymphocyte population, we performed T cell skewing experiments. We found the highest TSP-1 expression in Th1-skewed CD4 + cells and TCR activated CD8 + lymphocytes (Fig. 1e) .
To investigate the consequence of lymphocyte-derived TSP-1 on tumor growth, we generated bone marrow chimeras whereby Tsp1 -/-mice received either WT or Tsp1 -/-BM. Lewis lung carcinoma tumor cells injected into the flanks of these mice grew significantly more rapidly in mice with Tsp1 -/-BM compared to mice with WT BM, highlighting the tumor suppressive role of TSP-1 in BM-derived cells (Fig. S1b) . However, TSP-1 in the immune compartment expressed at endogenous levels was not sufficient to effectively suppress tumor growth (Fig. S1b) .
T cell derived TSP-1 inhibits tumor growth following LCMVa infection
Since our in vitro studies indicate that Th1-skewed CD4 + and CD8 + cells produced significantly elevated levels of TSP-1, we utilized the Armstrong clone of lymphocytic choriomeningitis virus (LCMVa), an acute type I virus, to activate the immune system. Type I-inducing infections are known to inhibit tumor growth in a T cell-dependent manner (15) . Interestingly, perforin and granzyme were dispensable for this inhibition, indicating that suppressing tumorigenesis was not due to tumor cell lysis (15, 16 ͳͳ after LPS stimulation but was not seen during in vitro T cell stimulation. The identity of this 100kDa band as TSP-1 was confirmed by Western blot on Tsp1 -/-splenocytes and mass spectrometry (Fig. S1d,e) .
To probe the functional significance of TSP-1 in T cells and to determine whether TSP-1 plays a role in abrogating tumor growth after immune stimulation, WT and Tsp1 -/-mice were inoculated with B16F10 melanoma cells intradermally and when tumors were palpable, mice were infected with LCMVa to induce a T cell response. LCMVa infection significantly inhibited tumor growth in WT mice by day 8
(p = 0.02), but had no effect on tumorigenesis in Tsp1 -/-mice (Fig. 2b) . Importantly, immune activation by LCMVa infection also suppressed growth of well-established, highly vascularized B16F10 tumors in WT but not Tsp1 -/-mice (Fig. 2c) . To determine whether the tumor suppressive effects of infection persisted after the peak of the immune response to LCMVa, we infected B16F10 tumor-bearing WT or
Tsp1
-/-mice and followed tumor growth for 17 days post-infection (Fig S2a) . (Fig. 2d) 
S2b)
Endothelial and stromal cell-derived TSP-1 are thought to be the predominant source of TSP-1.
To investigate whether the anti-tumor effect of TSP-1 was an immune-cell autonomous response or whether endothelial or stromal contribution of TSP-1 was necessary, we generated bone marrow (BM) (Fig. 3a,b) . In contrast, tumor growth was unaffected after LCMVa infection in WT hosts with Tsp1 -/-BM (Fig. 3c) .
Lymphocytes isolated from either WT or Tsp1 -/-mice were adoptively transferred into Rag1 -/-hosts, and mice were inoculated with B16F10 melanoma cells. LCMVa infection suppressed tumor growth more than two-fold in mice with WT lymphocytes, but had no effect on tumor growth in Rag1 -/-mice that received Tsp1 -/-T cells (Fig. 3d,e) . Adoptive transfer of either WT CD4 + or WT CD8 + T cells
into Rag1 -/-demonstrated that while CD4 cells partially inhibited tumor growth after infection, only CD8 + T cells significantly inhibit tumor growth after LCMVa infection (Fig. S3a) .
LCMVa infection inhibits tumor angiogenesis in a TSP-1 dependent manner
The upregulation of TSP-1 in activated lymphocytes implies a role for TSP-1 in immune cell function. Thus we examined both proliferation of Tsp1 -/-T cells and inhibition by VEGF and found no differences in comparison to WT T cells (Fig. 4a) . IL-4 and IFN-γ production were also unaffected by TSP-1 status (Fig. 4b,c) . To ensure that TSP1 loss did not affect the anti-viral response to LCMVa, we examined the ratio of IFN-γ producing CD4 + and CD8 + cells and the proportions of CD4 + and CD8 + T cells in the spleens of naïve or LCMVa-infected WT or Tsp1 -/-mice and found no differences (Fig. 4d,e) . ( Fig. 4h) and by Western blot analysis (Fig. 4g) . CD8 + T cells were purified from tumors harvested from LCMVa infected and non-infected mice and lysates probed for TSP-1 expression, showing a dramatic increase in TSP-1 in CD8 + T cells from tumors of LCMVa infected mice (Fig. 4g) . Cytospin preparations of CD45 + cells isolated from tumors harvested from LCMVa infected or non-infected mice and co-stained for TSP-1 and CD3 further indicated that TSP-1 is produced specifically by T cells within the tumor, and that the portion of TSP-1 + T cells increases 1.9-fold (p=0.01) in tumors from infected mice (Fig. 4i) .
Both WT and
Similar to previous reports showing that acute infections suppress tumor angiogenesis, we find a significant decrease in the microvessel density of tumors harvested from WT mice infected by LCMVa as compared to tumors from uninfected mice. To more fully characterize tumor angiogenesis after LCMVa infection, tumor sections were analyzed for the average total vessel number, number of visible lumens, and number of vessels >100μm per field. All of these parameters of angiogenesis were significantly decreased in tumors from WT mice after LCMVa infection (Fig. 5a,b) . Further, the number of NG2 + pericytes was decreased in tumors from LCMVa-infected WT mice indicating less stable vessels (Fig.   5a ). In contrast, no difference in angiogenesis was observed in tumors harvested from Tsp1 -/-mice, regardless of infection, implicating a requirement for TSP-1 to suppress tumor angiogenesis (Fig. 5a,b) .
Supporting a direct anti-angiogenic role for T cell-secreted TSP-1, conditioned media collected from in vitro stimulated WT but not Tsp1 -/-CD4 + or CD8 + T cells dramatically inhibited endothelial cell tube formation on Matrigel (Fig. 5c ).
Many cytokines also have anti-angiogenic effects. For example, IFN-γ suppresses tumor angiogenesis after acute infection by an unknown mechanism (14) . Thus to test whether TSP-1 functions downstream of IFN-γ, we probed for TSP-1 expression in Ifnγ -/-or Ifnγr -/-splenocytes after in vitro stimulation and found that TSP-1 expression was diminished in the absence of either IFN-γ or IFNγR, even though these cells had similar growth rates as WT splenocytes (Fig. 5d) . Regulation of TSP-1
Research. ͳͶ expression is not fully understood, although it has been shown to be a direct transcriptional target of the tumor suppressor p53. Thus we examined TSP-1 upregulation in p53 -/-CD4 + cells after TCR ligation and found that TSP-1 expression was still induced, obviating a need for p53 in TSP-1 upregulation in lymphocytes (Fig. 5e) .
We have reported that calcineurin-NFAT signaling could be regulating TSP-1 expression in lymphocytes (13) due to the presence of NFAT consensus sequences in the Tsp1 promoter. Addition of the calcineurin inhibitor, cyclosporin A (CsA), to activated T cells attenuated TSP-1 upregulation confirming our previous study implicating TSP-1 regulation by the calcineurin-NFAT signaling pathway in lymphocytes (13) (Fig. 5f) . Collectively, these data support an important role for TSP-1 in anti- Collectively, our data demonstrate that anti-angiogenic surveillance is a consequence of immune system activation in response to acute infection and that T cell-derived TSP-1 plays a key role inhibiting tumor angiogenesis.
Research.
on cell activity towards tumor cell lysis (31) . Additionally, hypoxia regulates polarization of both macrophages and neutrophils, and can promote a pro-tumor phenotype in innate immune cells (32, 33) .
The relationship between angiogenic suppression by T cell-derived TSP-1, the tumor microenvironment, and secondary skewing of infiltrating immune cells is complex and merits further study.
on October ʹ͵ was performed, and samples were stained for TSP-1 (red) and CD3 (green). Bar = 50 μm. The percent of
CD3
+ cells that were TSP-1 + was determined by counting. Graph represents percentages for individual cytospins (n=5 or 6, p<0.05). 
